PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33400951-4	2021	This report compares the ability of recombinant human ACE2 (rhACE2) to metabolize Ang III, Ang IV and Ang V, (4-8 pentapeptide) relative to Ang II to form corresponding des-omega-Phe metabolites.	rhace2	60-66	angiotensin converting enzyme 2	Homo sapiens	54-58
33852951-4	2021	The binding activity of rhACE2 to Spike protein of SARS-CoV2 was evaluated in S protein-overexpressed HEK293A cells (HEK293A-SP cells) through flow cytometry.	rhace2	24-30	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	34-39
33732940-5	2021	In addition, all three compounds showed potent anti-exopeptidase activity against recombinant human angiotensin-converting enzyme 2 (rhACE2) and inhibited the binding of rhACE2 with SARS-CoV-2 Spike (RBD) protein.	rhace2	133-139	angiotensin converting enzyme 2	Homo sapiens	100-131
33732940-5	2021	In addition, all three compounds showed potent anti-exopeptidase activity against recombinant human angiotensin-converting enzyme 2 (rhACE2) and inhibited the binding of rhACE2 with SARS-CoV-2 Spike (RBD) protein.	rhace2	170-176	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	193-198
32817951-5	2020	In addition, all three compounds showed potent anti-exopeptidase activity against recombinant human angiotensin converting enzyme 2 (rhACE2) and inhibited the binding of rhACE2 with SARS-CoV-2 Spike (RBD) protein.	rhace2	133-139	angiotensin converting enzyme 2	Homo sapiens	100-131
33368659-8	2021	Incubation with rhACE2 decreased traditional APs while increasing beneficial alternative APs, and Ang1-7 was significantly higher in the ARB + rhACE2 (880 pg/mL; 95% CI = 560-1383 pg/mL) vs ACEI + rhACE2 (455 pg/mL; 95% CI = 188-1104 pg/mL; P = .03) group.	rhace2	143-149	angiopoietin 1	Canis lupus familiaris	98-104
33368659-8	2021	Incubation with rhACE2 decreased traditional APs while increasing beneficial alternative APs, and Ang1-7 was significantly higher in the ARB + rhACE2 (880 pg/mL; 95% CI = 560-1383 pg/mL) vs ACEI + rhACE2 (455 pg/mL; 95% CI = 188-1104 pg/mL; P = .03) group.	rhace2	143-149	angiopoietin 1	Canis lupus familiaris	98-104
32864572-7	2020	We presume that restoration of normal functioning of renin-angiotensin system with recombinant human angiotensin-converting enzyme 2 (rhACE2), angiotensin (1-7) and angiotensin (1-9) may be an effective therapeutic measure but studies will be required to test this hypothesis and explore its possible role in treatment of COVID-19.	rhace2	134-140	angiotensin converting enzyme 2	Homo sapiens	101-132
33135833-2	2021	HYPOTHESIS/OBJECTIVES: Angiotensin receptor blockers (ARBs) would alter balance of APs and differences would be magnified in vitro by incubation of plasma samples with recombinant human ACE2 (rhACE2).	rhace2	192-198	angiotensin converting enzyme 2	Homo sapiens	186-190
34611521-3	2021	Recombinant human ACE2 (rhACE2) functionalized onto the surface of cytomimetic particles binds the receptor binding domain (RBD) of recombinant SARS-CoV-2 spike protein with high affinity and demonstrated a stoichiometric advantage over the use of soluble rhACE2.	rhace2	24-30	angiotensin converting enzyme 2	Homo sapiens	18-22
31254308-3	2019	Equilibrium concentrations of renin angiotensin aldosterone system (RAAS) APs differ in dogs with heart disease compared to healthy dogs and recombinant human ACE2 (rhACE2) alters relative concentrations of APs.	rhace2	165-171	renin	Canis lupus familiaris	30-35
31254308-3	2019	Equilibrium concentrations of renin angiotensin aldosterone system (RAAS) APs differ in dogs with heart disease compared to healthy dogs and recombinant human ACE2 (rhACE2) alters relative concentrations of APs.	rhace2	165-171	angiotensin converting enzyme 2	Homo sapiens	159-163
26245758-10	2015	The Ang II-mediated reductions of renal ACE2 and nephrin levels in ApoEKO mice were remarkably rescued by rhACE2 supplementation, along with augmentation of renal Ang-(1-7) levels.	rhace2	106-112	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	4-7
26245758-10	2015	The Ang II-mediated reductions of renal ACE2 and nephrin levels in ApoEKO mice were remarkably rescued by rhACE2 supplementation, along with augmentation of renal Ang-(1-7) levels.	rhace2	106-112	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	40-44
26245758-10	2015	The Ang II-mediated reductions of renal ACE2 and nephrin levels in ApoEKO mice were remarkably rescued by rhACE2 supplementation, along with augmentation of renal Ang-(1-7) levels.	rhace2	106-112	nephrosis 1, nephrin	Mus musculus	49-56
32264791-9	2020	rhACE2 (recombinant human ACE2) has completed clinical trials and efficiently lowered or increased plasma angiotensin II and angiotensin 1-7 levels, respectively.	rhace2	0-6	angiotensinogen	Homo sapiens	106-120
32428864-5	2020	In this view, we highlighted potential approaches to address ACE2-mediated SARS-CoV-2 virus, including 1) delivering an excessive soluble form of ACE2 (recombinant human ACE2: rhACE2) and 2) inhibition of the interaction between SARS-CoV-2 virus and ACE2 by some compounds with competitive effects (morphine and codeine).	rhace2	176-182	angiotensin converting enzyme 2	Homo sapiens	61-65
32428864-5	2020	In this view, we highlighted potential approaches to address ACE2-mediated SARS-CoV-2 virus, including 1) delivering an excessive soluble form of ACE2 (recombinant human ACE2: rhACE2) and 2) inhibition of the interaction between SARS-CoV-2 virus and ACE2 by some compounds with competitive effects (morphine and codeine).	rhace2	176-182	angiotensin converting enzyme 2	Homo sapiens	146-150
32428864-5	2020	In this view, we highlighted potential approaches to address ACE2-mediated SARS-CoV-2 virus, including 1) delivering an excessive soluble form of ACE2 (recombinant human ACE2: rhACE2) and 2) inhibition of the interaction between SARS-CoV-2 virus and ACE2 by some compounds with competitive effects (morphine and codeine).	rhace2	176-182	angiotensin converting enzyme 2	Homo sapiens	146-150
32428864-5	2020	In this view, we highlighted potential approaches to address ACE2-mediated SARS-CoV-2 virus, including 1) delivering an excessive soluble form of ACE2 (recombinant human ACE2: rhACE2) and 2) inhibition of the interaction between SARS-CoV-2 virus and ACE2 by some compounds with competitive effects (morphine and codeine).	rhace2	176-182	angiotensin converting enzyme 2	Homo sapiens	146-150
34611521-3	2021	Recombinant human ACE2 (rhACE2) functionalized onto the surface of cytomimetic particles binds the receptor binding domain (RBD) of recombinant SARS-CoV-2 spike protein with high affinity and demonstrated a stoichiometric advantage over the use of soluble rhACE2.	rhace2	24-30	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	155-160